Clinical Trial

A new drug targeting a genetic form of Parkinson's shows promise as its late-stage trial nears completion, offering hope for a precision treatment.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

A first-in-class oral therapy targeting cellular metabolism has entered patient trials, offering new hope for a disease-modifying treatment for eczema.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

Privo Technologies reports its PRV211 patch was well-tolerated in a key trial, offering a new, localized approach to preventing oral cancer recurrence.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

Ossium Health's groundbreaking study using banked bone marrow from deceased donors could solve the critical shortage of transplant matches for patients.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

PAQ Therapeutics advances its pan-KRAS degrader into human trials, backed by a $77M funding round, offering new hope for notoriously tough cancers.

Resalis Therapeutics hires a key leader from a Novo Nordisk acquisition to steer its novel RNA therapy, which aims for fat loss without muscle waste.

With a new CFO known for billion-dollar deals and a promising gout drug, Crystalys Therapeutics is gearing up for a pivotal run at the global market.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

An innovative absorbable implant shows promise in helping men regain continence faster after prostate cancer surgery, a major quality-of-life concern.

A clinical trial for D-Serine begins in Norway, testing a novel approach that could finally slow or halt the progression of Parkinson's disease.

Corvus Pharmaceuticals is set to unveil pivotal early data for its novel eczema drug, soquelitinib, a moment analysts call a critical milestone.

Genmab's antibody drug epcoritamab is the first of its kind to slow cancer progression in a Phase 3 trial for R/R DLBCL, offering a new path for patients.

A landmark Nature Medicine publication for OrsoBio's TLC-2716 offers new hope for millions suffering from severe lipid and liver disorders.

Results in Nature Medicine reveal an immunotherapy that may stop cancer before it starts in high-risk Lynch Syndrome carriers, heralding a new era of prevention.

A sudden collapse led to a rare cancer diagnosis for a NJ teen. His story of recovery highlights a therapy that targets tumors while sparing young minds.